Coissac Patrice Form 4 February 22, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB 3235-0287

Number:

January 31, Expires: 2005 Estimated average

0.5

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

			2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				•	ransaction			Director 10% Owner Officer (give title Other (specify below) below) SVP, Pres Alxn Pharm Int			
CHESHIRI	(Street) E, CT 06410		endment, Da nth/Day/Year	~	l		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative S	Securi	ities Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2. Deemed (Execution Date, if any (Month/Day/Year)		3. Transactic Code (Instr. 8)	4. Securit or(A) or Dis (Instr. 3, 4)	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock, par value \$.0001 per share	02/17/2011			M	36,100	, ,	\$ 14.08	75,041	D		
Common Stock, par value \$.0001 per share	02/17/2011			M	16,000	A	\$ 10.36	91.041	D		

Edgar Filing: Coissac Patrice - Form 4

Common Stock, par value \$.0001 per share	02/17/2011	S	24,494	D	\$ 92.41 (1)	66,547	D
Common Stock, par value \$.0001 per share	02/17/2011	S	27,606	D	\$ 93.25 (2)	38,941	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Relationships

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 14.08	02/17/2011		S		36,100	11/07/2006	11/07/2015	Common Stock	36,100
Option to Purchase Common Stock	\$ 10.36	02/17/2011		S		16,000	04/09/2006	01/09/2016	Common Stock	16,000

Reporting Owners

Reporting Owner Name / Address	Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other	
Coissac Patrice			SVP, Pres Alxn Pharm Int		

C/O ALEXION PHARMACEUTICALS, INC 352 KNOTTER DRIVE

Reporting Owners 2

CHESHIRE, CT 06410

Signatures

/s/ Patrice Coissac 02/22/2011

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$92.05 \$93.05. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$93.06 \$93.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3